<DOC>
	<DOCNO>NCT01632124</DOCNO>
	<brief_summary>Measuring lung function ( FVC , FEV1 , DLCO ) , treatment rituximab patient rheumatoid arthritis inflammatory myositis .</brief_summary>
	<brief_title>Rituximab-induced Pulmonary Function Changes</brief_title>
	<detailed_description>The objective study investigate whether rituximab ( RTX ) , drug commonly prescribe patient rheumatoid arthritis ( RA ) inflammatory myositis , associate subclinical interstitial lung disease ( ILD ) . Surrogate marker interstitial lung disease decrease force vital capacity ( FVC ) and/or diffuse capacity lung carbon monoxide ( DLCO ) . However , measurement lung function parameter indicate regular follow-up examination treatment RTX accord principle `` good clinical practice '' . We perform pulmonary function test ( spirometry ) include measurement DLCO patient RA , go treat RTX . A baseline lung function measurement perform immediately RTX therapy start . Follow-up measurement perform 2 week , 4 week , 8 week 6 month initiation RTX therapy . A reduction force vital capacity ( FVC ) &gt; 10 % fall &gt; 15 % DLCO define indicative ILD .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Myositis</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>Inclusion criterion : Patients establish diagnosis RA inflammatory myositis , de novo RTX treatment indicate Age &gt; 18 Informed consent patient Exclusion criterion : Acute infection Preexisting interstitial pulmonary disease Patients impair forced vital capacity ( FVC ) spirometry ( &lt; 80 % predict ) impaired DLCO ( &lt; 75 % predict ) . Pregnancy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2012</verification_date>
</DOC>